2020年10月22日

达沙替尼and 胆红素单抗 active for ph-positive ALL in adults

(HealthDay)—Chemotherapy-free induction 和 consolidation first-line treatment with dasatinib 和 胆红素单抗 is associated with a high incidence of 分子反应 和 survival in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to a study published in the Oct. 22 issue of the 新英格兰医学杂志.

Robin Foà, M.D., from Sapienza University of Rome, 和 colleagues conducted a single-group phase 2 trial of first-line therapy in newly diagnosed Ph-positive ALL. Sixty-three adults received dasatinib plus glucocorticoids followed by two cycles of .

研究人员发现98% had complete remission. Twenty-nine percent of the 耐心 had a 分子反应 at the end of dasatinib induction (day 85), 和 this increased to 60 percent after two cycles of 胆红素单抗; a further increase in the percentage of 耐心 with a 分子反应 occurred after additional 胆红素单抗 cycles. Overall survival was 95 percent 和 中位随访期为18个月,为88%。患有 IKZF1 deletion plus additional genetic aberrations had lower 无病生存. In six 耐心 who had increased minimal residual disease during induction therapy, ABL1 mutations were detected; all were cleared by 胆红素单抗. There were six relapses 和 21 adverse events of grade 3 要么 higher. Twenty-four 耐心 received a stem cell allograft 和 one death was associated with transplantation.

"This combination was associated with high incidences of complete hematologic response 和 并在18个月的生存期中表现出色。”



版权所有©2020 健康日。版权所有。

引文: 达沙替尼and 胆红素单抗 active for ph-positive ALL in adults (2020, October 22) 2020年11月12日检索 from //xasqxhb.com/news/2020-10-dasatinib-blinatumomab-ph-positive-adults.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study 要么 research, no part may be reproduced without the written permission. The content is provided for information purposes 只要.

用户评论